Drug safety is a barrier to the discovery and development of new androgen receptor antagonists

@article{Foster2011DrugSI,
  title={Drug safety is a barrier to the discovery and development of new androgen receptor antagonists},
  author={William R. Foster and Bruce D. Car and Hong Shi and Paul C. Levesque and Mary T. Obermeier and Jinping Gan and Joseph C. Arezzo and S S Powlin and Joseph E. Dinchuk and Aaron J Balog and Mark E. Salvati and Ricardo M Attar and Marco M. Gottardis},
  journal={The Prostate},
  year={2011},
  volume={71}
}
Androgen receptor (AR) antagonists are part of the standard of care for prostate cancer. Despite the almost inevitable development of resistance in prostate tumors to AR antagonists, no new AR antagonists have been approved for over a decade. Treatment failure is due in part to mutations that increase activity of AR in response to lower ligand concentrations as well as to mutations that result in AR response to a broader range of ligands. The failure to discover new AR antagonists has occurred… Expand
Androgen receptor antagonists for prostate cancer therapy.
TLDR
A concise overview of the clinically available antiandrogens and the experimental AR antagonists that tackle androgen action with a different approach is given. Expand
Androgen Receptor Antagonists in Castration-Resistant Prostate Cancer
TLDR
A review of 2 AR-targeted agents recently approved by the Food and Drug Administration and 2 direct antagonists, enzalutamide and ARN-509, that induce apoptosis without agonist activity in preclinical models shows great promise for patients with advanced disease. Expand
The Androgen Receptor as a Therapeutic Target for Castration-Resistant Prostate Cancer
TLDR
The biology of the AR is reviewed, the key aspects of therapy targeting the AR are discussed, the discovery and development of enzalutamide are reviewed, and other novel agents under investigation in clinical trials that target theAR are evaluated. Expand
Enzalutamide: Development from bench to bedside.
TLDR
The story of Enzalutamide's preclinical discovery, clinical development, and ultimate approval as a standard-of-care therapy for castration-resistant prostate cancer is presented. Expand
Expanding androgen- and androgen receptor signaling-directed therapies for castration-resistant prostate cancer.
TLDR
The most recent advances in AR-directed therapies for CRPC, promising new agents under development, cross-resistance, and mechanisms of resistance for the new-generation AR-targeted agents are reviewed. Expand
Mechanisms of drug resistance that target the androgen axis in castration resistant prostate cancer (CRPC)
  • T. Penning
  • Medicine
  • The Journal of Steroid Biochemistry and Molecular Biology
  • 2015
TLDR
The mechanisms of intrinsic and acquired drug resistance that target the androgen axis and how this might be surmounted are reviewed. Expand
Recent discoveries and developments of androgen receptor based therapy for prostate cancer
TLDR
The main focus of this review is to discuss the discoveries and developments of various therapies for prostate cancer, including several groups of drugs that have sparingly good anti-cancer activities, as well as a similar structure and behaviour. Expand
Discovery of ODM-201, a new-generation androgen receptor inhibitor targeting resistance mechanisms to androgen signaling-directed prostate cancer therapies
TLDR
ODM-201 is a potent AR inhibitor that overcomes resistance to AR-targeted therapies by antagonizing both overexpressed and mutated ARs and is currently in a phase 3 trial in CRPC. Expand
Enzalutamide, a Second Generation Androgen Receptor Antagonist: Development and Clinical Applications in Prostate Cancer
TLDR
The availability of enzalutamide is put into context with the five other agents that modify survival outcomes in metastatic castration resistant prostate cancer and some of the new challenges confronting the field regarding sequencing and combinations of these agents are discussed. Expand
ARN-509: a novel antiandrogen for prostate cancer treatment.
TLDR
ARS-509 exhibits characteristics predicting a higher therapeutic index with a greater potential to reach maximally efficacious doses in man than current AR antagonists, and offers preclinical proof of principle for ARN-509 as a promising therapeutic in bothCastration-sensitive and castration-resistant forms of prostate cancer. Expand
...
1
2
3
4
5
...

References

SHOWING 1-10 OF 26 REFERENCES
Discovery of BMS-641988, a novel and potent inhibitor of androgen receptor signaling for the treatment of prostate cancer.
TLDR
In mature rats, BMS-641988 strongly inhibited androgen-dependent growth of the ventral prostate and seminal vesicles and was highly efficacious in the LuCaP 23.1 human prostate xenograft model, inducing stasis throughout the approximately 30-day dosing. Expand
Development of a Second-Generation Antiandrogen for Treatment of Advanced Prostate Cancer
TLDR
The diarylthiohydantoins RD162 and MDV3100 are characterized, two compounds optimized from a screen for nonsteroidal antiandrogens that retain activity in the setting of increased androgen receptor expression that appear to be promising candidates for treatment of advanced prostate cancer. Expand
Treatment options for androgen-independent prostate cancer.
TLDR
Standard treatment options and promising new drugs and combination therapies under investigation for androgen-independent prostate cancer are summarized. Expand
Antitumour activity of MDV3100 in castration-resistant prostate cancer: a phase 1–2 study
TLDR
The results of this phase 1-2 trial validate in man preclinical studies implicating sustained androgen-receptor signalling as a driver in this disease. Expand
Mechanisms of androgen-refractory prostate cancer.
TLDR
When prostate cancer is localized in the prostate, the treatment of choice is prostatectomy or irradiation, however, when the tumor relapses or is already metastatic at diagnosis, therapy is problematic. Expand
Antitumor activity of MDV3100 in a phase I/II study of castration-resistant prostate cancer (CRPC).
  • H. Scher, T. Beer, +6 authors M. Fleisher
  • Medicine
  • Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2009
TLDR
MDV3100 is a promising candidate for the treatment of prostate cancer assessed by PSA, imaging, CTC, and time on treatment, and data suggest a dose-response trend and consistency across endpoints. Expand
Tolerability of Nonsteroidal Antiandrogens in the Treatment of Advanced Prostate Cancer.
  • Mcleod
  • Medicine
  • The oncologist
  • 1997
TLDR
Bicalutamide appears to have some advantage over flutamide and nilutamide in terms of tolerability, and the reverse is true for hot flashes, which are a side effect of castration. Expand
Tolerability, efficacy and pharmacokinetics of bicalutamide 300 mg, 450 mg or 600 mg as monotherapy for patients with locally advanced or metastatic prostate cancer, compared with castration
To evaluate the pharmacokinetics, tolerability and effect on endocrinology of bicalutamide given as once‐daily monotherapy at doses of >150 mg to patients with locally advanced (M0) or metastaticExpand
Identification and optimization of a novel series of [2.2.1]-oxabicyclo imide-based androgen receptor antagonists.
TLDR
A novel series of [2.2.1]-oxabicyclo imide-based compounds were identified as potent antagonists of the androgen receptor and shown to have potent in vivo efficacy after oral dosing in the CWR22 human prostate tumor xenograph model. Expand
Monotherapy with nilutamide, a pure nonsteroidal antiandrogen, in untreated patients with metastatic carcinoma of the prostate. The Italian Prostatic Cancer Project.
TLDR
The results indicate that nilutamide as a single agent has an acceptable toxicity and a moderate activity, and may maintain sexual interest in a discrete number of cases, and whether monotherapy with nonsteroidal antiandrogens offers a valid option in the palliation of advanced disease remains to be seen in comparative prospective trials. Expand
...
1
2
3
...